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There are no commercially available, small, receptor-speciﬁc P2X1 ligands. There are several synthetic
derivatives of the natural agonist ATP and some structurally-complex antagonists including compounds
such as PPADS, NTP-ATP, suramin and its derivatives (e.g. NF279, NF449). NF449 is the most potent and
selective ligand, but potencies of many others are not particularly high and they can also act at other P2X,
P2Y and non-purinergic receptors. While there is clearly scope for further work on P2X1 receptor
pharmacology, screening can be difﬁcult owing to rapid receptor desensitisation. To reduce desensiti-
sation substitutions can be made within the N-terminus of the P2X1 receptor, but these could also affect
ligand properties. An alternative is the use of ﬂuorescent voltage-sensitive dyes that respond to mem-
brane potential changes resulting from channel opening. Here we utilised this approach in conjunction
with fragment-based drug-discovery. Using a single concentration (300 mM) we identiﬁed 46 novel leads
from a library of 1443 fragments (hit rate ¼ 3.2%). These hits were independently validated by measuring
concentration-dependence with the same voltage-sensitive dye, and by visualising the competition of
hits with an Alexa-647-ATP ﬂuorophore using confocal microscopy; confocal yielded kon
(1.142  106 M1 s1) and koff (0.136 s1) for Alexa-647-ATP (Kd ¼ 119 nM). The identiﬁed hit fragments
had promising structural diversity. In summary, the measurement of functional responses using voltage-
sensitive dyes was ﬂexible and cost-effective because labelled competitors were not needed, effects were
independent of a speciﬁc binding site, and both agonist and antagonist actions were probed in a single
assay. The method is widely applicable and could be applied to all P2X family members, as well as other
voltage-gated and ligand-gated ion channels.
This article is part of the Special Issue entitled ‘Fluorescent Tools in Neuropharmacology’.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The P2X1 purinergic receptor, is a transmembrane ligand-gated
ion channel that is distributed in cells of the blood, such as platelets
and polymorphonuclear neutrophils, and in the smooth muscle of
organs such as the urinary bladder, vas deferens, arteries and in-
testines (Gever et al., 2006; White et al., 2013; Darbousset et al.,gn; ATP, Adenosine triphos-
x: þ44 1223 334100.
r Ltd. This is an open access article2014). Their activation results in the opening of an integral cation
channel that leads to membrane depolarisation and calcium entry.
Currently there is clinical potential for P2X1-selective ligands
that has not been met (Gunosewoyo and Kassiou, 2010). For
example, platelets maintain blood vessel integrity after injury and
their activation is the ﬁrst event in the process of haemostasis that
prevents blood loss. In healthy individuals endothelium-derived
inhibitors (prostacyclin and nitric oxide) prevent activation, but
upon damage to blood vessels a local loss of these inhibitors fa-
cilitates platelet activation by molecules such as exposed collagen
and diffusible secondary agonists such as ADP, thromboxane A2 and
thrombin (Jackson, 2007). Activation intimately relies upon
increased cytosolic Ca2þ, and cell-surface P2X1 receptors are major
contributors as they amplify the responses that cause blood clottingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fung et al., 2012). All steps in platelet activation are potential tar-
gets for anti-thrombotics, but current treatments, such as Clopi-
dogrel, Prasugrel, Ticlopidine and aspirin, can also cause unwanted
bleeding. In contrast, P2X1 receptors are only important under high
shear stress such as that found in narrow and stenotic vessels, the
very places where blood clots are most dangerous. Consequently,
P2X1 receptor inhibition has a lower bleeding risk because under
normal arterial ﬂow the receptors are unaffected and normal hae-
mostasis is maintained. This lower risk makes P2X1 receptors a
desirable target for preventing blood clots.
In addition to the antithrombotic potential of P2X1 receptor
antagonists, there is also strong evidence that these inhibitors
could be combined with a1A-adrenoreceptor antagonists to pro-
duce a highly efﬁcient and fully reversible non-hormonal male
contraceptive. Joint adrenergic and P2X1 receptor inhibition
blocks sperm transport by preventing the smooth muscles around
the vas deferens from contracting, causing reversible infertility
without the undesirable sexual, behavioural, physiological, and
psychological side effects that are seen with hormonal drugs
(White et al., 2013). As there is already an existing and widespread
use of a1-adrenoceptor antagonists for the treatment of disorders
such as hypertension, panic, anxiety and benign prostatic hyper-
plasia, only the development of a suitable P2X1 receptor antago-
nist is required before the beneﬁt of this pharmacological strategy
can be realised.
One means to identify new drug candidates for the P2X1 re-
ceptor is fragment-based drug-discovery (FBDD), an efﬁcient and
rational approach that is becoming widely adopted by industry
and academia (Murray et al., 2012; de Graaf et al., 2013; Joseph-
McCarthy et al., 2014). The chemical space of molecules has
been enumerated up to 17 atoms of C, N, O, Cl and S (termed
heavy atoms), following simple rules of stability and synthetic
feasibility, forming the GDB-17 database that contains 167 billion
structures (Reymond et al., 2012). Because this number is so vast,
industry typically screens smaller compound libraries (100,000 þ)
at a single concentration. However, even this library size is
resource-intensive, does not always identify effective ligands and
can be hindered by a legacy of previous targets (Macarron, 2006).
It has therefore become recognised that screening smaller com-
pounds (or fragments) can be more effective. Using FBDD, 1/
diverse chemical space can be efﬁciently described by smaller
numbers of lower molecular weight and lower complexity com-
pounds, 2/lower complexity raises the chance of identifying
protein-ligand interactions (Hann et al., 2001), 3/small fragment
libraries (~1000 compounds) typically result in a higher hit rate
than when screening drug-like compounds (Schuffenhauser et al.,
2005; Albert et al., 2007; Siegal et al., 2007; Chen and Hubbard,
2009; Gupta et al., 2009), 4/hit fragments are easier to optimize
to improve their afﬁnities and drug-like properties, and 5/FBDD is
design-intensive rather than resource-intensive (Rees et al.,
2004). Using this method we have had previous success in
identifying novel drugs for other ligand-gated ion channel targets
(Thompson et al., 2012; Verheij et al., 2012; Thompson et al.,
2013).
Here we describe the use of FBDD in the search for P2X1 re-
ceptor ligands. Owing to the need formedium-throughput, reduced
material costs, and the difﬁculties that the very rapid desensitisa-
tion of P2X1 receptors can create for electrophysiological-based
methods, a ﬂuorescence-based approach was used.
2. Materials and methods
2.1. Materials
Alexa-647-ATP was from Life Technologies (CA, USA). Human P2X1 (Accession:
P51575) subunit cDNA was provided by Richard Evans (Leicester University, UK).2.2. Plasmids
A FLAG-tagged human P2X1 subunit expression construct was created by fusion
PCR. The fragment was cloned together with an IRES-IFP1.4 (Shu et al., Science 2009;
324 no.5928) fusion PCR product as three point ligation into the MluI/SpeI digested
pLV-T backbone (Marquis et al., 2009). The bicistronic mRNA expressed from the
EF1alpha promoter codes for a c-terminal FLAG-tagged P2X1 protein and IFP1.4. The
pLV-tTR-Krab-Blast vector was created by exchanging the IRES-dsRed cassette from
pLV-tTR-Krab-dsRed with an IRES-Blasticidin expression cassette. All constructs
were veriﬁed by DNA sequencing.
2.3. Cell lines
HEK 293T cells were ﬁrst transduced with pLV-tTR-Krab-Blast to create the
HEK293-tTR-Krab-Blast cell line. After selection of transduced cells with Blasticidin,
this cell line was transduced with pLV-P2X1-IRES.IFP1.4 to create the inducible
P2X1-FLAG-IRES-IFP1.4 cell line.
2.4. Virus production
FuGene HD (Promega, WI, USA) was used to transfect HEK 293T cells with pLV-
tTR-Krab Blast and pLV-P2X1-FLAG-IRES-IFP1.4, respectively along with
pCMVDR8.91 and pMD2.G according to established methods (Wiznerowicz and
Trono, 2003). Lentiviral supernatants were collected 48, 72 and 96 h post trans-
fection and ﬁltered through a 0.45 mM polyethersulfone sterile ﬁlter (Millipore
Corp, MA, USA). For transduction, HEK 293T cells were incubated with lentiviral
supernatants supplemented with 5 mg mL1 polybrene (hexadimethrine bromide,
Sigma Aldrich St. Louis, MO, USA). After 7 h, polybrene was diluted to 2.5 mg mL1
by the addition of fresh DMEM/10% FBS, and the procedure was repeated for two
days.
After expansion of the double transduced cells, doxycycline and biliverdine
were added to the medium for 48 h and highly IFP1.4 positive cells were collected
by ﬂuorescence-activated cell sorting (FACS) to yield a highly transduced cell pool.
High level expression was further optimized by generating a clonal cell line. This
was achieved by visual inspection of Alexa-647-ATP binding using confocal
microscopy.
2.5. Screening library
The screening compounds are commercially available via IOTA Pharmaceuticals
(IOTA Pharmaceuticals Ltd, Cambridge, UK). This library was derived from a larger
proprietary compound collection and the selectionwas loosely based on the rule-of-
three criteria and aimed at maximal structural diversity (Congreve et al., 2003; de
Graaf et al., 2013).
2.6. Plate preparation
For each screen two 96-well microplates plates were prepared. The ﬁrst of
these plates contained 80 different fragments in separate wells of columns 2e11, an
ATP concentrationeresponse (1 mMe3 nM in 3-fold dilutions) in column 1, and a
saline control in column 12. In the second plate, columns 1e11 contained 30 mM
ATP and column 12 was an ATP concentrationeresponse (1 mMe30 nM in 3-fold
dilutions).
2.7. Fluorometric microplate assays
Assays were performed using methods similar to those described elsewhere
(Thompson et al., 2010). In brief, fragments were assessed for both agonist and
antagonist activities using HEK 293T cells stably expressing doxycycline-inducible
P2X1 receptors incubated for 45 min with 50 ml of a ﬂuorescent dye sensitive to
membrane potential (dye FLIPR Membrane Potential Assay Kit, Molecular Devices,
Wokingham, UK) that was dissolved in buffer (mM: 115 NaCl, 1 KCl, 1 MgCl2, 1
CaCl2, 10 HEPES, 10 D-Glucose, pH 7.4). Dye-loaded cells were transferred to
a FlexStation III (Molecular Devices) where compound applications were made
without removing the dye. At recording intervals of 1.2 s, baseline ﬂuorescence
was recorded for 20 s, followed by a further 60 s after the addition of compounds.
Ultimately two applications were made to the same cells. In the ﬁrst, agonist
activity was assessed by adding 50 ml novel fragment (ﬁnal
concentration ¼ 300 mM) to each well. Following the completion of the ﬁrst
application, a second 50 ml application of 30 mM ATP (ﬁnal concentration ¼ 10 mM)
was then added to the same cells. A response upon the ﬁrst (fragment) application
and an absence of a response on the second (ATP) application indicated agonist
activity followed by inhibition as a result of receptor desensitisation. In contrast,
an antagonist did not elicit a response in the ﬁrst application and inhibited the
subsequent ATP response. The absence of a response during the ﬁrst application
and a robust ATP response upon the second application indicated that the frag-
ment was inactive.
In addition to testing fragments, the reproducibility of each experiment was
assessed by including an ATP concentrationeresponse in the ﬁrst column and a
saline control in the last column of the ﬁrst application. This ensured ATP activation
at appropriate concentrations at the start of the experiment and that buffer alone
did not alter the baseline ﬂuorescence. The saline control in the ﬁrst application also
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second application. This allowed cell viability to be assessed by comparing the ATP
concentrationeresponse at the start of the ﬁrst application with the ATP concen-
trationeresponse at the end of the second application. At least two replicates were
performed and compounds scored as hits when activity was observed on two plates.
Following the identiﬁcation of active compounds from these single-concentration
screens, the same procedure was used to subsequently test hits for concentration-
dependence to conﬁrm their activity and to obtain a measure of their potency.
Measurements from these concentration-dependence experiments were ﬁtted
using Eq. (1) below.
Applying novel compounds and a known agonist to the same cells had several
advantages, namely that 1) agonist, antagonist and allosteric modulators were
identiﬁed in a single screen, 2) which reduced material costs, 3) the 16 min time
period between the ﬁrst and second applications allowed fragments to equilibrate in
the presence of the cells before the second ATP application was added and, 4)
reproducibility was improved because the same cells were subjected to both
applications.2.8. Data analysis
Measurements from the FlexStation III were recorded using the integrated
software SoftMax Pro v5.4.5 (Molecular Devices). Analysis of concentration-
dependence was performed with GraphPad Prism v5.00 (GraphPad Software, San
Diego, CA, USA). Peak ﬂuorescence was measured at a range of ligand concentrations
and normalised to the maximum peak ﬂuorescence for the same experiment. The
mean and standard error of the mean (S.E.M.) for a series of measurements was
plotted against agonist or antagonist concentration and iteratively ﬁtted to the
following equation:
y ¼ Imin þ
Fmax  Fmin
1þ 10ððlogR50xÞnH Þ
(1)
where Fmin is the baseline ﬂuorescence, Fmax is the peak ﬂuorescence, R50 is the
concentration of ligand needed to generate a half-maximal response, x is the ligand
concentration and nH is the Hill slope.2.9. Confocal microscopy
Live cells were routinely visualised in phosphate buffered saline (PBS (mM);
155 NaCl, 3.0 Na2HPO4, 1.0 KH2PO4, pH 7.4). Static and time-lapse images were
collected using a FV300 laser-scanning confocal microscope with either an
Olympus UplanFLN 40  NA1.30 oil immersion objective and a 60 mm confocal
aperture, or a PlanApo 60x NA1.42 oil immersion objective and a 60 mm confocal
aperture. Images were exported to ImageJ v1.47 (National Institutes of Health, USA)
and the Multi Measure plugin (Optinav Inc, WA, USA) used for analysing regions of
interest.2.10. Kinetic analysis
Kinetic parameters were determined according to the following model of a
simple bimolecular binding scheme:
Lþ R) *kon
koff
LR (2)
where L is the free ligand concentration, R is receptor concentration, LR is the
ligandereceptor complex and kon and koff are the microscopic association and
dissociation rate constants. In a simple scheme such as this, the equilibrium disso-
ciation constant (Kd) is equal to the ratio of dissociation to association rate constants,
such that:
Kb ¼
k1
kþ1
(3)
According to a one site binding model of the type shown, the observed rates of
association and dissociation can be used to estimate kþ1 and k1:
1
.
toff ¼ k1 (4)
and
1=ton ¼ kþ1½L þ k1 (5)
where ton refers to the rate at which ﬂuorescence increases, toff refers to the rate
that ﬂuorescence decreases and [L] is concentration of the ligand used.
Association was determined by measuring the increase in ﬂuorescence seen at
the cell surface following the application of different concentrations of Alexa-647-
ATP. Dissociation was measured by 3 rapid washes with PBS on Alexa-647-ATP
equilibrated cells. Intracellular and background ﬂuorescence was also routinely
monitored as a control.3. Results
3.1. Effects of a known agonist and antagonists
Application of NaATP or MgATP to HEK 293T cells stably
expressing the P2X1 receptor produced concentration-dependent
ﬂuorescent responses when loaded with a voltage-sensitive dye
(Figs. 1 and 2). Plotting peak ﬂuorescent amplitude against a series
of agonist concentrations allowed the data to be ﬁtted with Eq. (1).
For NaATP this gave a pEC50 of 5.26 ± 0.09 (EC50 ¼ 5.49 mM, n ¼ 22)
and Hill slope of 0.9 ± 0.2, and for MgATP a pEC50 of 4.85 ± 0.07
(EC50 ¼ 14.1 mM, n ¼ 20) and Hill slope of 1.0 ± 0.1 (Fig. 2A and B).
Untransfected HEK 293T cells did not respond to either NaATP or
MgATP (Fig 1B). Agonist responses were completely inhibited by
the known P2X1 receptor antagonists NF449 (pIC50 ¼ 4.68 ± 0.06,
IC50 ¼ 20.1 mM, Hill Slope ¼ 1.1 ± 0.2, n ¼ 7; Fig. 2C) and suramin
(pIC50 ¼ 3.76 ± 0.15, IC50 ¼ 174 mM, Hill Slope ¼ 1.5 ± 0.7, n ¼ 7;
Fig. 2D).
3.2. Fragment screening
1443 fragments were screened at least twice and scored as hits
when activity was observed on two plates. Using a ﬁnal concen-
tration of 300 mM, a total of 46 active fragments were identiﬁed as
hits, which is an overall hit rate of 3.2% that compares well with
other FBDD screens (Albert et al., 2007; Siegal et al., 2007; Chen and
Hubbard, 2009; Davies et al., 2009; Gupta et al., 2009). At the end of
this ﬁrst screen the single point measurements were used to
forecast the EC50 and IC50 values of the fragments using Eq. (1) and
assuming a Hill slope of 1 (Fig 1C).
For identiﬁed hits, a second screen was used to verify
concentration-dependence and to compare the resultant EC50 and
IC50 values with those predicted from the hit screens.
Concentration-dependence was examined using the same design
as the hit screens, except a range of concentrations were used
rather than a single concentration. The cells were similarly sub-
jected to a second application of 30 mM ATP (10 mM ﬁnal) to assess
both agonist and antagonist behaviours. These results show that for
the majority (39/46), concentration-dependence was conﬁrmed,
representing an 85% success rate for identifying hits in the initial hit
screens and subsequently measuring concentration-dependence.
When these EC50 and IC50 values were compared to estimates
from the single point measurements they were generally higher
(Fig 1C).
3.3. Properties of Alexa-647-ATP
To further validate the results of fragment screening another
ﬂuorescence method was used. Here we observed the competition
between our hit fragments and the ﬂuorophore Alexa-647-ATP,
using confocal microscopy (Fig 3). As the properties of Alexa-647-
ATP at P2X1 receptors are largely unknown it was ﬁrst necessary
to make measurements of Alexa-647-ATP alone.
Application of Alexa-647-ATP to P2X1 expressing cells produced
a concentration-dependent ﬂuorescent responsewhen loadedwith
a voltage-sensitive dye (Fig 3A). Plotting peak ﬂuorescent ampli-
tude against a series of concentrations gave a pEC50 of 5.24 ± 0.04
(EC50¼ 5.75 mM, n¼ 5) and Hill slope of 1.1 ± 0.1, that was similar to
the values for NaATP and MgATP.
To characterise Alexa-647-ATP in more detail, confocal micro-
scopy was used to make kinetic measurements. Following the
application of Alexa-647-ATP to P2X1-expressing HEK 293T cells,
the subsequent increase in ﬂuorescence was well ﬁtted by mono-
exponential functions (Fig. 3B, Table 1). When the reciprocal of
the rates of increase were plotted against Alexa-647-ATP
Fig. 1. Typical data from ﬂuorescent microplate assays using stably expressed doxycycline-inducible P2X1 receptors in a HEK 293T cell line. (A) An ATP concentrationeresponse is
included in column 1 of application 1, while column 12 contains saline alone. For hit screening 300 mM of different fragments are added to each well in columns 2e10. Because
column 12 of application 1 contains saline alone, an ATP concentrationeresponse can be performed on the same cells during application 2; ATP concentrationeresponse curves at
the start and end of the experiment can then be compared to conﬁrm the consistency of the responses throughout the experimental period. To make visualisation of large datasets
simpler, peak ﬂuorescent responses are binned and assigned colours by the acquisition software, ranging from the largest ﬂuorescence change (Black) to the smallest (white).
Fragments are deﬁned as agonists, antagonist, or inactive depending upon the responses to the two applications; see the methods section for a description. (B) The top panel shows
a lack of ﬂuorescent response following the addition of varying concentrations of ATP (arrow) to uninduced HEK 293T cells. The bottom panel shows raw data from an identical ATP
application (arrow) on doxycycline-induced HEK 293T cells. The data in the bottom panel is from column 1 of Fig. 1A, plotted as a change in ﬂuorescence over time. In both panels a
baseline is recorded for 20 s before the addition of ATP. Such data can be used to plot concentrationedependence curves similar to those shown in Fig. 2. When hit fragments are
identiﬁed at a single (300 mM) concentration, their concentrationedependence can be later assessed using the same experimental protocol as the ATP standards shown here.
Although P2X1 receptors desensitise rapidly when measured using electrophysiological techniques, the ﬂuorometric method shown here has much longer lasting responses as the
cells are not voltage-clamped (depolarisation is longer lived); similar long-lived responses are seen for the rapidly desensitising 5-HT3 receptor when using the same dye (Price and
Lummis, 2005). (C) A comparison of pIC50 values estimated from single-point measurements (300 mM) and those calculated from concentration-dependence curves. The straight
line shows the vector along which the single-point predictions and measured potencies would be equal. (D) A comparison of pIC50 values determined for identiﬁed hit fragments
(closed circles), ATP (open circle) and the established P2X1 antagonists, NF449 and suramin (open circles). Each point represents a different compound and the average afﬁnity of all
the fragments is shown as a horizontal bar.
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linearly with the ligand concentration, as predicted by Eq. (2)
(Fig. 3C). The association rate (kon) was determined from the
slope of the 1/ton curve and the dissociation rate constant from the
y-axis intercept. The association rate for Alexa-647-ATP was
1.142 106M1 s1, and the dissociation ratewas 0.136 s1, giving a
Kb of 119 nM (Eq. (3)); direct measurements of dissociation gave a
similar value for koff (0.407 min1, Fig 3D) and, consistent with asimple bi-molecular reaction scheme, the dissociation rate of
Alexa-647-ATP was independent of the initial Alexa-647-ATP con-
centration (data not shown).
3.4. Confocal assessment of identiﬁed hits
Addition of 150 nM Alexa-647-ATP to P2X1 receptor-expressing
HEK 293T cells resulted in a rapid increase in cell-surface
Fig. 2. Properties of stably expressed doxycycline-inducible P2X1 receptors in a HEK 293T cell line. (AeB) Concentrationeresponse curves for NaATP and MgATP, measured using a
voltage-sensitive dye. (CeD) Concentrationeinhibition of 10 mM ATP responses by known P2X1 antagonists NF449 and suramin. (E) Example data for one of the identiﬁed
fragments.
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rescence was not present on the surface of non-induced cells (Fig
4B) or on the surface of cells pre-treated with 250 mM NF449 (Fig
4C) or 5 mM NaATP (Fig 4D). Cell-surface ﬂuorescence was still
seen following pre-treatment with suramin (Fig 4E). Fluorescence
was not seen inside labelled cells, indicating that Alexa-647-ATP
was not cell-permeable.
Of the identiﬁed ligands from hit screens, 94% (43/46) also
prevented binding of Alexa-647-ATP (Fig 4F). These results suggest
that the majority of identiﬁed hit fragments compete with Alexa-647-ATP and further conﬁrm our identiﬁcation of hits. Negative hits
were similarly assessed and did not compete with Alexa-647-ATP.3.5. Structural diversity of the identiﬁed hit fragments
A high structural diversity of identiﬁed hits is illustrated by the
Scaffold Classiﬁcation Approach (SCA) as developed by Xu (2002).
The plot in Fig 5 shows the high structural diversity of both agonists
and antagonists as hits can be found throughout the scaffold space.
Fig. 3. Kinetics of Alexa-647-ATP interactions at P2X1 receptors. (A) Alexa-647-ATP shows the same concentration-dependence as NaATP when measured using the voltage-
sensitive dye. (B) Using confocal microscopy, the association of Alexa-647-ATP was determined by measuring the increase in cell-surface ﬂuorescence following the application
of different concentrations of this ligand. Upon application of Alexa-647-ATP a saturable increase in ﬂuorescence was observed and was best ﬁtted with a mono-exponential curve
to yield kobs (see Table 1). In this example the change in ﬂuorescence following the addition of 0.3 mM Alexa-647-ATP is shown for both the background (red) and for ﬁve cells
(black). (C) A plot of the average kobs against the concentration of Alexa-647-ATP was ﬁtted by linear regression (R2 ¼ 0.89) to give the rates of association (slope) and dissociation
(intercept at y ¼ 0). The afﬁnity of Alexa-647-ATP was calculated using these kinetic values (Eq. (3)) and gave a Kd of 119 nM. (D) Dissociation was measured after rapidly washing
Alexa-647-ATP equilibrated P2X1-expressing HEK 293T cells with fresh PBS (t ¼ 0). Dissociation was best-ﬁtted with mono-exponential ﬁts that gave an average dissociation rate
(koff ¼ 0.40 min1) that was similar to the value calculated in panel (C). Similar to panel A, there is low background ﬂuorescence (red) when compared to cell-surface ﬂuorescence
(black).
Table 1
Rates of association of Alexa-647-ATP.
Alexa-647-ATP (mM) kobs (min1) n
0.15 0.28 ± 0.06 5
0.5 0.79 ± 0.08 7
1.5 1.73 ± 0.14 4
5 5.86 ± 0.58 6
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To accurately characterise the pharmacology of a receptor it is
necessary to have suitable ligands and experimental methods. Here
we describe a ﬂuorometric microplate assay for identifying candi-
date P2X1 receptor ligands using fragment-based drug discovery.
This ﬂuorescence-based assay provides a ﬂexible and cost-effective
solution for identifying new leads from compound libraries, and
uses a voltage-sensitive dye that also makes it widely relevant for
screening other ligand-gated ion channels. The assay also has
several advantages over some traditional approaches such as
radioligand binding and electrophysiology as it does not focus on a
single binding site (unlike competition-based methods), it is suit-
able for extended compound pre-incubations, it is able to identify
both agonists and antagonists in a single screen, and it overcomes
some of the challenges associated with the rapid desensitisation of
the P2X1 receptor.46 hits were identiﬁed from a total of 1443 fragments and the
activity of the majority of these conﬁrmed by demonstrating
concentration-dependence and observing competition with Alexa-
647-ATP. In our initial hit-screens relatively high concentrations of
fragments were used (300 mM), which is typical of fragment
screening where higher starting concentrations are often needed
and potency is later improved by chemical elaborations (Scott et al.,
2012). Further experiments to determine their EC50 and IC50 values
indicated that the majority of these candidate ligands (74%) had
micro-molar afﬁnities. Comparable levels of potency have been
reported elsewhere when using a fragment-based approach,
including targets as diverse as b2-adrinergic receptors, histamine
receptors, protein kinase C, cAMP-speciﬁc 30,5'-cyclic phosphodi-
esterase 4D and acetylcholine binding protein, b-secretase and
BACE-1 (Murray et al., 2007;Wang et al., 2010; Scott et al., 2012; de
Graaf et al., 2013). Importantly, when we have used a similar
ﬂuorometric approach on other ligand-gated ion channels we also
identiﬁed novel fragments, showing the general applicability of the
approach (Thompson et al., 2012; Verheij et al., 2012; Thompson
et al., 2013).
Different analytical methods often give varying potencies for the
same ligand and for NaATP and MgATP our EC50 values were
elevated when compared to previously published work (Rettinger
and Schmalzing, 2004). The standards suramin and NF449 also
had IC50 values that were higher than those reported elsewhere;
although literature values vary from mMe nM, depending upon the
Fig. 4. Confocal imaging of ﬂuorescently-labelled P2X1 receptors expressed on the cell-surface of stably expressing HEK 293T cells. (A) Following an application of 150 nM Alexa-
647-ATP a clear halo of ﬂuorescence was visible on the cell-surface. Despite there being no washing steps in the preparation, the level of background ﬂuorescence is negligible. (B)
No ﬂuorescence was seen on uninduced HEK 293T cells. (C, D) Fluorescent-labelling was not seen at P2X1 receptor-expressing HEK 293T cells that were pre-incubated with 250 mM
NF449 or 5 mM non-labelled ATP. (E) Suramin did not alter cell-surface ﬂuorescence. (F) Pre-incubation with 43/46 hits affected cell-surface labelling with Alexa-647-ATP. Panel F
shows an example of one of these. All panels in this ﬁgure were measured using identical conditions. Scale ¼ 50 mm.
Fig. 5. A scaffold-based classiﬁcation approach (SCA) illustrates the high structural
diversity of the identiﬁed hits. Cyclicity is a measure for the distribution of cyclic and
acyclic parts of the structure, and complexity is a measure for size and shape of the
scaffold (Xu, 2002).
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However, these differences have been seen with voltage-sensitive
dyes in other studies and may result from the use of a secondary
reporter (the dye) to reveal currents in cells that are not voltage-
clamped. Furthermore, if the apparent EC50 of the agonist is
elevated, higher concentrations of antagonists may be needed to
overcome the dextral shift of the inhibition curves caused bycompetition. Despite these differences, the assay was able to assay
know ligands and identify ligands, while concentration-
dependence provided a validation of the single point screens and
indicated that the method provides a suitable screen for early hit
identiﬁcation that can be followed later by higher-resolution ap-
proaches on lower numbers of selected compounds (Kennedy et al.,
2007; Jarvis and Khakh, 2009; El-Ajouz et al., 2012).
The EC50 for Alexa-647-ATP was close to the values for MgATP
and NaATP, consistent with the comparable EC50 values of ATP and a
ﬂuorescent ATP derivative BODIPY-TR-ATP that have been reported
at P2X3 receptors (Kowalski et al., 2014). These results suggest that
these ﬂuorescent agonists are suitable for studying ATP activation
of P2X receptors using other ﬂuorometric methods, such as in the
voltage-clamp ﬂuorometry reported by Bhargava et al. (2013) and
in the single molecule microscopy by Barden et al. (2015). The
ﬁnding that conjugation of a ﬂuorophore does not affect the
functional response is consistent with the crystal structures of ATP
bound to P2X4 where it is clear that the ribose 20 and 30 positions
onto which the dyes are substituted face out of the orthosteric
binding site and would not be expected to overly affect ligand
binding (Hattori and Gouaux, 2012). Other reports have shown low
nanomolar EC50 values for both ATP and Alexa-647-ATP, but these
are only apparent when desensitisation is dramatically slowed by
substituting the N-terminus of P2X1 with that found in the more
slowly desensitising P2X2 receptor (Rettinger and Schmalzing,
2004; Bhargava et al., 2013). Here, for the ﬁrst time, a nanomolar
afﬁnity for Alexa-647-ATP was instead directly measured by
determining koff and kon using confocal microscopy. Signiﬁcantly,
the afﬁnity derived from these values (Kd ¼ koff/kon) was similar to
M.-D. Ruepp et al. / Neuropharmacology 98 (2015) 13e2120that measured using single molecule microscopy (Barden et al.
2015).
The afﬁnity of Alexa-647-ATP was sufﬁciently high to enable
live-cell imaging of expressed P2X1 receptors with very low back-
ground ﬂuorescence. P2X1 and P2X3 receptors have a similar EC50
for ATP, and the latter has also been labelled with a ﬂuorescent ATP
derivative (Kowalski et al., 2014). In contrast, we could not detect
any measureable ﬂuorescence on the cell surface of HEK 293T cells
expressing P2X4 or P2X7 receptors (data not shown), consistent
with the lower potencies that these two receptor subtypes typically
display for their ligands (Jarvis and Khakh, 2009). Of the 46 hits
identiﬁed in our initial screens, 43 also reduced the Alexa-647-ATP
ﬂuorescent signal in subsequent confocal assays, a 94% success rate
that is slightly higher than previous reports where two methods
were used to validate compounds acting on ligand-gated ion
channels (Thompson et al., 2010); in these studies hits from ﬂuo-
rescent microplate assays were validated by competition with a
radiolabelled antagonist. For the remaining 3 fragments, 1 dis-
played neither concentration-dependence nor competition with
Alexa-647-ATP suggesting that it was a false positive, while the
other 2 fragments may be non-competitive or not potent enough to
produce a measureable response in both assays. This may also be
the reason that suramin caused functional inhibition in our ﬂuo-
rescent microplate assays, but no competition was seen under the
confocal microscope, as both competitive and non-competitive
modes of action have been described for this highly promiscuous
ligand (Wong et al., 2000; Trujillo et al., 2006; Varani et al., 2008b).
Previously, this combination of a functional assay and an assess-
ment of orthosteric competition provided useful insights into the
mechanisms of action of ligands and guided later medicinal
chemistry efforts (Verheij et al., 2012; Thompson et al., 2013). An
orthogonal approach has therefore become increasingly common,
with the different methods often producing complimentary results.
To date there have been very few descriptions of P2X1 receptor
ligands when compared to many other ligand-gated channels, but
here we have shown that fragment-based drug discovery is a
suitable approach for identify new leads (Gunosewoyo and Kassiou,
2010). Those that were identiﬁed belong to one of several structural
clusters, as illustrated by the distribution of compounds in the SCA
plot in Fig 5, and provide an ideal starting point for further me-
dicinal chemistry. One of the clusters contains analogues of the
tricyclic carbamazepines, and similar compounds have been re-
ported elsewhere in the literature. Initially these were found to
antagonise P2X4 receptors, but during the preparation of our
manuscript have also been reported to bind to P2X1 receptors with
micromolar afﬁnities (Tian et al., 2014). Finding analogues of these
compounds in our fragment library was reassuring and the po-
tencies we measured for themwere in the same micromolar range.
Within other structural clusters there are several unique scaffolds
which are now part of our on-going efforts to determine structur-
eeactivity relationships with the aim of optimising their potency
and selectivity at P2X1 receptors.
The ﬂuorescent methods presented here were developed to
overcome the challenges of having limited quantities of test frag-
ments and the need to rapidly screen large numbers of them on a
ligand-gated ion channel. Elsewhere the Ca2þ-sensitive dye Fluo-4
has been used to assess P2X4 ligands, supporting our notion that
ﬂuorescence-based methods provide a valuable research tool
(Hernandez-Olmos et al., 2012). Other methods such as surface
plasmon resonance (SPR), nuclear magnetic resonance (NMR), X-
ray structure determination and mass spectrometry are also widely
used for fragment screening, but are less commonly used on ligand-
gated ion channels (de Kloe et al., 2009). Radioligandmethods offer
an alternative approach, but in our hands the high cost of a suitable
P2X1 receptor radioligandmade it impractical for routine screening(Varani et al., 2008a, 2008b). Electrophysiology could have been
another possible alternative, but limits pre-application times and is
complicated by rapid P2X1 receptor desensitisation that makes it
difﬁcult to measure the IC50 values of slowly equilibrating ligands
(El-Ajouz et al., 2012; Bhargava et al., 2013). Methods such as these
are therefore more practical for sensitive follow-up experiments on
a smaller number of selected ligands and their derivatives, where
complex phenomena such as modes of action and structur-
eeactivity relationships can be studied at higher resolution. In
contrast, the ﬂuorometric microplate method described here is a
time- and cost-effective method that uses a voltage-sensitive dye
that does not depend upon the availability of a high-afﬁnity ligand,
is ion-independent, can distinguish agonists from antagonists and,
as the method is not limited to interactions at a single binding site,
requires no presumptions regarding the site of action (Hulme and
Trevethick, 2010). The assay is ideal for course screening to iden-
tify ligand candidates with actions at P2X1 receptors and whose
properties can be subsequently improved by elaboration and
further assessed using more time-consuming, higher-resolution
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